Clinical trials: injection or injectable or infusion or IV or syringe or subcutaneous, open to volunteers
- Drug or intervention injection OR injectable OR infusion OR IV OR syringe OR subcutaneous
- Status Open to volunteers
Shock
Effect of Balanced Saline Solution and Albumin on Volume Expansion in Shock Patients
To compare the direct effect of sodium acetate ringer injection or albumin on volume expansion in shock patients, and to provide reference for volume resuscitation strategy in shock patients
- Trial name
- NCT05463471
- Testing
- Compound sodium acetate ringer injection, Albumin
- Volunteers
- 500 people
- Sponsor
- Peking Union Medical College Hospital
Acute Myeloid Leukemia
Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia
This is a clinical trial of Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the treatment of patients with relapsed / refractory acute myeloid leukemia.
- Trial name
- NCT05445011
- Testing
- Fludarabine + Cyclophosphamide + TAA05 Cell Injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Neuroblastoma
Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma
Neuroblastoma (NB) is the most common extracranial solid tumor of embryonal origin in children. According to the International Neuroblastoma Risk Group (INRG) staging criteria and the International Neuroblastoma Staging System…
- Trial name
- NCT05303727
- Testing
- Anti Thymocyte Globulin, Fludarabine, Cyclophosphamide injection
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
A study of APRIL CAR-T cells therapy for patients with BCMA/TACI positive relapsed and/or refractory multiple myeloma
- Trial name
- NCT04657861
- Testing
- APRIL CAR-T cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Zhejiang University
Fissure in Ano
Complex Treatment of a Chronic Anal Fissure
This study is aimed at studying the efficacy and safety of treating chronic anal fissure with botulinum toxin versus lateral subcutaneous sphincterotomy.
- Trial name
- NCT03855046
- Testing
- IncobotulinumtoxinA 50 U Intramuscular Powder for Solution, Lateral subcutaneous sphincterotomy.
- Where
- 7 sites in Russia
- Volunteers
- 340 people
- Sponsor
- State Scientific Centre of Coloproctology, Russian Federation
Multiple Myeloma
A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)
This study is a multi-center, single-arm clinical study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamic characteristics of CT103A as the first-line treatment in newly diagnosed high-risk multiple myeloma…
- Trial name
- NCT05181501
- Testing
- Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
- Where
- 4 sites in China
- Volunteers
- 20 people
- Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
Acute Myeloid Leukemia, Non-hodgkin's Lymphoma
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
A Study of CD 70 CAR T for patients with CD70 positive malignant hematologic diseases
- Conditions
- Acute Myeloid Leukemia, Non-hodgkin's Lymphoma, Multiple Myeloma
- Trial name
- NCT04662294
- Testing
- CD70 CAR T-cells
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Zhejiang University
Stomach Neoplasms, Peritoneal Metastases
HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction
HIPEC-AS01 is an open, prospective, single-center phase II clinical study, which will include "cT4aNxM0, P0 or cTxNxM1, P1" patients with gastric or esophagogastric junction adenocarcinoma, to evaluate the efficacy and safety of…
- Trial name
- NCT05095467
- Testing
- HIPEC, Paclitaxel-albumin, Tegafur-gimeracil-oteracil potassium
- Volunteers
- 157 people
- Sponsor
- Xuefei.Wang
B-cell Non-Hodgkin's Lymphoma
A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
This study is a single-armed, open-label,multicenter Phase 1/2 study to evaluate the safety and efficacy of CT120 in subjects with relapsed/refractory B-cell non-Hodgkin's lymphoma.
- Trial name
- NCT05091541
- Testing
- Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection
- Volunteers
- 125 people
- Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
Irritable Bowel Syndrome, Fecal Microbiota Transplantation
Fecal Microbiota Transplantation for Irritable Bowel Syndrome
Fecal microbiota transplantation (FMT) is a strategy that infuses a fecal suspension containing a healthy donor's microbiota into a patient's gut to restore his/her intestinal microbiome.
- Trial name
- NCT03613545
- Testing
- fecal microbiota transplantation, probiotics, antibiotics or antidepressants
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Guangzhou First People's Hospital
Obesity, Type 2 Diabetes
Gut Hormones and Roux en Y Gastric Bypass
The purpose of this study is to assess whether the changes in gut hormones seen following Roux en Y Gastric Bypass surgery are responsible for some of the beneficial effects seen post-operatively.
- Trial name
- NCT01945840
- Testing
- Roux en Y Gastric Bypass Surgery, Gut hormone infusion, Very low calorie diet
- Where
- United Kingdom
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Retinoblastoma, Chemotherapy Effect
Topotecan and Melphalan for Retinoblastoma
The purpose of this study is to evaluate topotecan and melphalan for retinoblastoma patients.
- Trial name
- NCT04799002
- Testing
- Topotecan, Melphalan
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Ovarian Cancer, Epithelial
Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer
CHIMOVIP is a study to determine the best therapeutic strategy in patient with ovarian advanced cancer.
- Trial name
- CHIMOVIP (NCT03025477)
- Testing
- CC0 - Carboplatin (IV) - Paclitaxel (IV), CC0 - Cisplatin (IP) - Epirubicin (IV), CC>0 - Carboplatin (IV)- Paclitaxel (IV)
- Where
- 7 sites in France
- Volunteers
- 84 people
- Sponsor
- Groupe Hospitalier Diaconesses Croix Saint-Simon
Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma
A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
A study of CTA101 UCAR-T cell injection in patients with relapsed or refractory CD19+ B-line hematological malignancy
- Trial name
- NCT04227015
- Testing
- CTA101
- Where
- China
- Volunteers
- 72 people
- Sponsor
- He Huang
Relapse Multiple Myeloma, Refractory Multiple Myeloma
A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
Clinical Trial for the safety and efficacy of humanized BCMA-targeted CAR-T cells therapy for refractory/relapsed multiple myeloma
- Trial name
- NCT04670055
- Testing
- BCMA Targeted CAR T-cells
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang University
Relapse Multiple Myeloma
A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy
Clinical trial for the safety and efficacy of CS1-targeted CAR-T Cells therapy for relapsed multiple myeloma after BCMA CAR-T cells therapy
- Trial name
- NCT04541368
- Testing
- CS1 Targeted CAR T-cells
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang University
Infectious Diseases, Hematological Malignancies
LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies
A study of LMP1 CAR-T for patients with LMP1 positive infectious diseases and hematological malignancies
- Trial name
- NCT04657965
- Testing
- LMP1 CAR T-cells
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Zhejiang University
Acute Myeloid Leukemia
NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
A Study of NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia.
- Trial name
- NCT04658004
- Testing
- NKG2D CAR T-cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Zhejiang University
Acute Leukemia, Mielodysplasic Syndrome
Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning
Because the anti-leukemic activity of busulfan, this dug is largely used in graft conditioning but in elderly and/or cormobid patienth an excess of toxicity is observed.
- Conditions
- Acute Leukemia, Mielodysplasic Syndrome, Myeloproliferative Neoplasm
- Trial name
- BUSEQ (NCT04451200)
- Testing
- Busulfan Injection
- Volunteers
- 82 people
- Sponsor
- Institut Paoli-Calmettes
Mucosal Melanoma, Neoadjuvant Treatment
Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma
This study is a randomized ,single center clinical study which is designed to investigate whether combination of Pembrolizumab with Lenvatinib could improve pCR rate and consequent survival in resectable mucosal melanoma.
- Trial name
- NCT04622566
- Testing
- Lenvatinib, Pembrolizumab
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Peking University Cancer Hospital & Institute